FOOD SCIENCE ›› 2013, Vol. 34 ›› Issue (23): 271-275.doi: 10.7506/spkx1002-6630-201323055

Previous Articles     Next Articles

Effect of Ganoderma atrum Polysaccharide on cAMP/PKA Pathway in Mouse Colon Cancer Cells

ZHANG Shen-shen,NIE Shao-ping,XIE Ming-yong*   

  1. State Key Laboratory of Food Science and Technology, Nanchang University, Nanchang 330047, China
  • Received:2013-07-05 Revised:2013-11-05 Online:2013-12-15 Published:2014-01-03
  • Contact: XIE Ming-yong E-mail:myxie@ncu.edu.cn;xmync@sina.com.cn

Abstract:

Ganoderma atrum polysaccharide-1 (PSG-1) has been reported to be natural chemopreventive in several types
of tumor cells. In our previous study, we found that PSG-1 could significantly inhibit the tumor growth. We hypothesized
that PSG-1 might exert its anticancer effect by activating cAMP/protein kinase A (PKA) pathway. The present study was
designed to analyze the effect of PSG-1 on the cAMP/PKA pathway in mouse colon cancer CT26 cells. The cells were
treated with 0, 50, 100 μg/mL, and 200 μg/mL PSG-1 or 20 μg/mL 5-fluorouracil, respectively, for 48 h. The ratio of
apoptotic CT26 cells was measured by flow cytometry analysis. The cellular cAMP content was tested using a cAMP assay
kit. The activity of PKA was measured using a PKA activity assay kit. Reverse transcript-polymerase chain reaction (RT-PCR)
was used to analyze the mRNA expressions of PKA and cAMP response element binding protein (CREB) of the cells. The
results showed that PSG-1 significantly induced the apoptosis of the CT26 cells and that cAMP concentration in the cells
treated with PSG-1 was dramatically increased by 20.18%, 38.67% and 56.25% (P < 0.05), respectively. The PKA activity
was increased by 15.42%, 18.76% and 38.26%, respectively. The mRNA levels of both PKA and CREB of the cells treated
with PSG-1 were increased. The current study suggests that PSG-1 activates the cAMP/PKA pathway in colon cancer cells
by inducing cAMP production and activating PKA protein.

Key words: Ganoderma atrum polysaccharide, CT26 cells , cAMP/PKA pathway

CLC Number: